Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Overexpression of Genes May Predict Positive Response to Treatment

By LabMedica International staff writers
Posted on 14 Sep 2016
Overexpression of centromere (CEN) and kinetochore (KT) gene activity was linked to poor prognosis in several types of cancer, and a genetic signature based on 14 of these genes was shown to have potential for predicting both outcome of the disease and tumor response to chemotherapeutic and radiation treatments.

Chromosomal instability (CIN) is a hallmark of cancer that contributes to tumor heterogeneity and other malignant properties. More...
Abnormal CEN and KT function causes CIN through chromosome missegregation, leading to aneuploidy, rearrangements, and micronucleus formation.

In order to test the hypothesis that dysregulation of CEN/KT genes caused chromosomal abnormalities that contributed to tumor formation and could be used as a biomarker for predicting patient prognosis and response to therapy, investigators at the Lawrence Berkeley National Laboratory (Berkeley, CA, USA) focused on genes regulating the function of centromeres and kinetochores – the essential sites on chromosomes for spindle fiber attachment during cell division.

The investigators examined several public cancer databases that provided information on DNA mutations and chromosome rearrangements, the presence and levels of specific proteins, the stage of tumor growth at the time the patient was diagnosed, treatments given, and patient status in the years following diagnosis and treatment.

This information combined with the mapping of 31 genes involved in regulating centromere and kinetochore function enabled the investigators to generate a CEN/KT gene expression score (CES) based on patient outcomes either with or without treatments.

In a paper published in the August 31, 2016, online edition of the journal Nature Communications, the investigators reported that overexpression of 14 CEN/KT genes was observed consistently in a wide spectrum of cancer types and correlated with the level of genomic instability in diverse tumors and with adverse tumor properties in a cancer-type-specific manner. High CES values correlated with increased levels of genomic instability and several specific adverse tumor properties, and indicated poor patient survival for breast and lung cancers, especially early-stage tumors.

In contrast, the high degree of chromosomal instability rendered cancer cells more vulnerable to the effects of chemotherapy or radiation therapy, and the CES signature could be used to predict whether such therapy was likely to be effective.

“The overexpression of a specific centromere protein resulted in extra spindle attachment sites on the chromosomes,” said senior author Dr. Gary Karpen, senior researcher in the division of biological systems and engineering at the Lawrence Berkeley National Laboratory. “This essentially makes new centromeres functional at more than one place on the chromosome, and this is a huge problem because the spindle tries to connect to all the sites. If you have two or more of these sites on the chromosome, the spindles are pulling in too many directions, and you end up breaking the chromosome during cell division. So overexpression of these genes may be a major contributing factor to chromosomal instability, which is a hallmark of all cancers.”

“The history of cancer treatment is filled with overreaction,” said Dr. Karpen. “It is part of the ethics of cancer treatment to err on the side of over treatment, but these treatments have serious side effects associated with them. For some people, it may be causing more trouble than if the growth was left untreated.”

Related Links:
Lawrence Berkeley National Laboratory


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
Urine Chemistry Control
Dropper Urine Chemistry Control
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.